About this trial
While surgical resection remains the primary treatment approach for symptomatic or growing meningiomas, radiotherapy represents an auspicious alternative in patients with meningiomas not safely amenable to surgery. Biopsies are often omitted in light of potential postoperative neurological deficits, resulting in a lack of histological grading and (molecular) risk stratification. In this prospective explorative biomarker study, extracellular vesicles in the bloodstream will be investigated in patients with macroscopic meningiomas to identify a biomarker for molecular risk stratification and disease monitoring.
Eligibility criteria
Qualifiers
confirmed meningioma (histologically or MRI/DOTATOC-PET CT)
macroscopic tumor in MRI (either as definitive RT, or following subtotal resection or relapse)
indication for radiotherapy
completed wound healing after surgical intervention)
Disqualifiers
previous or known tumor diseases < 5 years ago
previous (cerebral) radiotherapy
simultaneous chemo/immunotherapy
evidence that the patient cannot adhere to the study protocol (e.g., non-compliance)
Trial design
Treatments tested in this trial
- Explorative biomarker study